Novartis and Mochida end Japanese Diovan pact
This article was originally published in Scrip
Executive Summary
Novartisand Mochida have let lapse a Japanese agreement for the local co-promotion of Novartis's antihypertensive Diovan (valsartan). The firms said that the early 2007 partnership had achieved its aims and that the Swiss group would market and promote the angiotensin II antagonist alone from the beginning of this year. IMS data showed that Diovan was the second biggest-selling prescription drug in Japan in the quarter to September 30th, with reimbursement-level sales rising by 5% to ¥32.4 billion ($346.2 million).
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.